Hepatitis E virus infection in sheltered homeless persons, France
Sylvie Larrat, Stéphanie Gaillard, Monique Baccard, Lionel Piroth, Patrice Cacoub, Stanislas Pol, Christian Perronne, Fabrice Carrat, Patrice Morand

To cite this version:
Sylvie Larrat, Stéphanie Gaillard, Monique Baccard, Lionel Piroth, Patrice Cacoub, et al.. Hepatitis E virus infection in sheltered homeless persons, France. Emerging Infectious Diseases, 2012, 18 (6), pp.1031-1031. 10.3201/eid1806.110632. hal-02648629

HAL Id: hal-02648629
https://hal.inrae.fr/hal-02648629
Submitted on 29 May 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution 4.0 International License
for prion researchers to refer to the normal nonpathogenic conformation of prions as “cellular prion proteins” (3). When these normal cellular prion precursors convert to pathogenic prion proteins, the transmissible conformations are characterized by β-pleated sheets rather than the normal α-helix structure, and they do not elicit an immune response (4).

Lawrence B. Schonberger and Robert B. Schonberger
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (L.B. Schonberger); and Yale University School of Medicine, New Haven, Connecticut, USA (R.B. Schonberger)
DOI: http://dx.doi.org/10.3201/eid1806.120271

References

Address for correspondence: Lawrence B. Schonberger, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop A30, Atlanta, GA 30333, USA; email: lbs1@cdc.gov

Hepatitis E Virus Infection in Sheltered Homeless Persons, France

To the Editor: Kaba et al. (1) reported a seroprevalence of 11.6% for hepatitis E virus (HEV) among homeless persons in the city of Marseille, located in southern France, and a multivariate analysis suggested that injection drug use (IDU) was an independent risk factor for HEV transmission. We disagree with this reported finding.

We conducted a retrospective subanalysis of results from a multicenter therapeutic trial assessing HEV seroprevalence among HIV/hepatitis C co-infected patients in France (2). Serum samples from 84 IDU patients, enrolled during 2000–2002 were stored at −80°C. The mean ± SD age of the patients was 39 ± 4 years; 53 (63%) were men, 19 (23%) were born outside France, and 38 (45%) were living in southern France. HEV antibodies were tested with the same assay as that used by Kaba et al. (1), and HEV RNA was detected by using a real-time reverse transcription PCR amplifying open reading frame 3 (3). None of the patients had detectable IgM against HEV or HEV RNA. Test results for 3 (3.6%) patients were positive for HEV IgG. Two of them lived in southern France, resulting in a 5.3% (2/38) HEV prevalence for IDU patients living in this region, where HEV IgG prevalence for healthy blood donors has reportedly ranged from 9% to 16.6% (4).

The difference between our study, which demonstrated low HEV IgG prevalence in IDU patients, even in southern France, and the results from Kaba et al. (1) must be interpreted with caution because there were several epidemiologic differences between the 2 populations. Moreover, there is a risk for false-negative serologic results for HIV patients because of impaired immunity, and the predictive value of serologic testing is probably low because of the artificially low HEV prevalence reported for this population. Despite these limitations, our study suggests that the high prevalence of HEV infection among homeless persons in southern France was not influenced by IDU, but reflected the general epidemiology of HEV in this region.

Sylvie Larrat, Stéphanie Gaillard, Monique Baccard, Lionel Piroth, Patrice Cacoub, Stanislas Pol, Christian Perronne, Fabrice Carrat and Patrice Morand for the French National Agency for Research on AIDS and viral hepatitis HC02 Ribavic Study Team
Author affiliation: University Hospital of Michallon, Isère, Grenoble, France
DOI: http://dx.doi.org/10.3201/eid1806.110632

References

Address for correspondence: Sylvie Larrat, Laboratoire de Virologie, Département des Agents Infectieux, CHU de Grenoble BP 2170 Grenoble Cedex 9 38043, France; email: slarrat@chu-grenoble.fr
In Response: The letter of Larrat et al. (1) raises interesting questions, but we disagree with the authors’ conclusion. Their study and ours investigated the seroprevalence of infection with hepatitis E virus (HEV) (1,2); however, the 2 studies examined different populations. We studied homeless persons, for whom analysis of risk factors associated with HEV infection emphasized injection drug use (2). This represented independent data: injection drug use was a behavior associated with increased anti-HEV prevalence; a causal relationship between injection drug use and hepatitis E was not inferred. In contrast to our study population, the population studied by Larrat et al. comprised patients who were co-infected with HIV and hepatitis C virus and who reported injection drug use as the route of HIV or hepatitis C virus transmission: a distinctly different population from homeless persons (1). It is likely that behavior of HIV-positive and HIV-negative intravenous drug users is not the same. Moreover, late seroconversion, persistent seronegativity, and seroreversion of IgG against HEV have been reported for severely immunocompromized patients, including some infected with HIV (3–5), which brings up the question as to whether prevalence of IgG against HEV is underestimated among severely immunocompromized persons infected with HIV.

Seroprevalence studies of different populations, especially those with differing immune responses, cannot lead except by chance to the same result. Of note, we recently reported that HEV seroprevalence was 2.3% among injection drug users infected with HIV (5).

Mamadou Kaba
and Philippe Colson

Author affiliations: Timone University Hospital, Marseille, France; and University of the Mediterranean (Aix-Marseille-II), Marseille

DOI: http://dx.doi.org/10.3201/eid1806.111412

References


Address for correspondence: Philippe Colson, Pôle des Maladies Infectieuses et Tropicales Cliniques et Biologiques, Fédération de Bactériologie-Hygiène-Virologie, Centre Hospitalo-Universitaire Timone, 264 Rue Saint-Pierre, 13385 Marseille CEDEX 05, France; email: philippe.colson@ap-hm.fr